Johnson & Johnson

Johnson & Johnson Q3 earnings show steady revenue growth, stronger margins and bullish guidance—highlighting a resilient pharma pipeline, new consumer products, and solid cash‑flow for shareholder returns.

Johnson & Johnson’s inclusion in a high‑yield ETF highlights its steady dividend track record and solid financial resilience, making it a top pick for income‑focused investors.

Johnson & Johnson’s Q1 earnings reveal how Tremfya, new ophthalmic drugs, and supply‑chain shifts could boost EPS amid tariff risks and a contracting healthcare sector.

Johnson & Johnson’s latest earnings reveal a resilient mix of pharma, consumer and device revenue, rising margins, and a strong R&D pipeline, but regulatory risks from talc litigation and emerging obesity‑treatment scrutiny remain key factors for in…

Johnson & Johnson’s Q1 earnings show steady growth, strategic oncology pricing, patient‑access programs, and M&A plans to mitigate patent cliffs and boost future revenue.

Johnson & Johnson Q1 earnings reveal steady growth, consumer‑health resilience, and device innovation, while spotlighting R&D risks and regulatory challenges.

Johnson & Johnson’s MedTech spin‑off reshapes device innovation, accelerates FDA paths, and aims to unlock shareholder value in personalized medicine.

Johnson & Johnson’s Q1 earnings reveal strong profitability and a growing pipeline of gene‑editing, bispecific antibody and targeted kinase therapies, while navigating U.S. drug‑pricing and tariff policy.

Johnson & Johnson’s $500 M co‑funding with Royalty Pharma to advance JNJ‑4804 and EMA approval of subcutaneous Darzalex highlight its dual‑track strategy, expanding inflammatory disease and multiple‑myeloma reach while balancing risk and growth pros…

Johnson & Johnson’s Q1 2026 outlook: modest revenue lift, EPS dip, and new oral psoriasis drug PJ‑102 poised for market success amid Humira patent cliff and strategic M&A moves.